Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: A Hoosier Oncology Group trial

Gura Sonpavde, Rafat Ansari, Paul Walker, David F. Sciortino, G. Thomas Gabrys, Ann Murdock, René Gonin, Lawrence H. Einhorn

Research output: Contribution to journalArticle

25 Scopus citations


Forty-six evaluable patients with recurrent small-cell lung cancer were entered on a phase II Hoosier Oncology Group (HOG) protocol evaluating bolus doxorubicin 40 mg/m2 followed by paclitaxel 175 mg/m2 over 3 hours. Courses were repeated every 3 weeks for a maximum of 6 courses. Therapy was well- tolerated with grade III neurotoxicity in 5 patients (11%), grade III/IV emesis in 5 (11%), and grade III mucositis in 2 patients. One patient had grade IV myalgias and one patient had grade III cardiotoxicity. The main toxicity was myelosuppression. Twenty-nine patients (63%) had grade IV and 8 (17%) grade III granulocytopenia. Nine patients (20%) were hospitalized for granulocytopenic fever. There was no treatment-related mortality. Nineteen of 46 patients (41%) had an objective response, including 3 complete remissions. Two of 14 patients with refractory disease (progression less than 3 months after initial therapy) responded, compared to 17 of 32 (52%) with sensitive disease (progression beyond 3 months of initial chemotherapy regimen).

Original languageEnglish (US)
Pages (from-to)68-70
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number1
StatePublished - Feb 1 2000



  • Doxorubicin
  • Paclitaxel
  • Second-line chemotherapy
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this